Eli Lilly to outsource half of research by 2010

While other big pharma companies have been making headlines with big layoffs and global restructuring plans, Eli Lilly has been steadily chipping away at its own strategy--quietly outsourcing jobs and services for research and manufacturing around the world as it gradually lowers its head count. About 40 percent of its IT work has already been outsourced with outside partners expected to handle half of its research work by 2010.

- read the report on Lilly's plans from the Indianapolis Star

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.